On March 21, BioEq, Russia’s first commercial R&D center for early phase studies has been opened in St. Petersburg. The research and development complex is a joint project of Biofund of the Russian Venture Company (RVC) and the BioEq company
RVC Seed Fund has successfully withdrawn from the capital of Diastam. The Fund's share in the project was 5.5% with return on investment being 60%. The share of RVC Seed Fund was bought by Science, Technology, Medicine
RVC Seed Fund together with DI-Group is going to invest 18.5 million rubles in the project of the manual controller iMotion. The investment will be used to expand the device's capabilities, in particular, compatibility with various operating systems – Android, iOS, Linux, and Mac
Human Stem Cell Institute – HSCI, OJSC, a Russian biotech company developing and implementing products and services in the field of cellular, genetic, and post-genomic technologies – announced signing an Investment Agreement with RVC Biofund
Russian and Korean biotech companies Infectex, Ltd. and Qurient, Ltd. have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurient’s Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine
OncoMax presented its research at the 5th European Multidisciplinary Meeting for Urological Cancer (EMUC), which was held on 15-17 November 2013 in Marseille, France. Dr. Ilya Tsimafeyeu, a scientific advisor of OncoMax, has received a special award for the best research “FIRST PRIZE” for his study "FGF- and VEGF-dependent angiogenesis and its targeting"